Moderna's mFlusiva becomes the first mRNA flu vaccine approved by the FDA for adults 50 and older.

The clearance paves the way for the first preventive flu shot based on mRNA technology and completes a dramatic regulatory turnaround.

The FDA’s approval is welcome news, and will hopefully open the door to much faster production of an effective vaccine to counter any future flu pandemic.

The vaccine, developed by Moderna, is approved for adults ages 50 to 64 and those 65 and older, who face the highest risk of severe illness.